Compare NWTG & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | GLMD |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.6M |
| IPO Year | N/A | 2014 |
| Metric | NWTG | GLMD |
|---|---|---|
| Price | $1.85 | $1.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 173.3K | ★ 6.3M |
| Earning Date | 11-13-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,931,000.00 | N/A |
| Revenue This Year | $120.41 | N/A |
| Revenue Next Year | $70.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 178.24 | N/A |
| 52 Week Low | $0.82 | $0.74 |
| 52 Week High | $49.80 | $3.61 |
| Indicator | NWTG | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 53.66 |
| Support Level | $1.49 | $0.81 |
| Resistance Level | $1.75 | $0.99 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 91.02 | 49.70 |
Newton Golf Co Inc is a technology-forward golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company's expanding portfolio includes golf shafts, putters, grips, and other golf-related accessories designed for golfers of all skill levels. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf, as well as through mass merchants and corporate customers in the Americas, Asia, and Europe.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.